Siranbio

Based in Suzhou, China and founded in 2022, Suzhou Shian Biotechnology Co. , Ltd. , trading as Siranbio, is engaged in the research and development of siRNA therapeutics. In December 2025, Siranbio raised a pre-series A funding from new investor Zhongqi Capital.

The company specializes in developing innovative small interfering RNA (siRNA) drugs to address unmet clinical needs across various disease areas, including viral infections, cardiovascular and metabolic disorders, autoimmune diseases, and central nervous system conditions. Key product lines include the SA1211 dual-target siRNA, aimed at achieving functional cures for hepatitis B, and the lead product SA030, a weight reduction siRNA drug. The company's revenue is generated by sales of their innovative therapies, positioned as solutions in the biopharmaceutical sector. The pre-series A funds raised will significantly accelerate the preclinical research and clinical development of the company's core technologies, further advancing the implementation of its commercialization strategy.